{
    "clinical_study": {
        "@rank": "89214", 
        "acronym": "OML0113", 
        "arm_group": [
            {
                "arm_group_label": "OCT 0.1% vs. Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "0.1 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)"
            }, 
            {
                "arm_group_label": "OCT 0.15% vs. Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "0.15 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)"
            }, 
            {
                "arm_group_label": "OCT 2.0% vs. Placebo", 
                "arm_group_type": "Active Comparator", 
                "description": "0.2 % Octenidine dihydrochloride vs. Placebo (0.9 % sodium chloride solution)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this clinical trial is to identify the most efficacious octenidine\n      dihydrochloride concentration regarding bacterial count reduction in comparison to a placebo\n      in the oral cavity."
        }, 
        "brief_title": "Dose Finding Study to Assess Octenidine Mouthwash Concentrations in Comparison to Placebo", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Gingivitis", 
        "condition_browse": {
            "mesh_term": "Gingivitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with mild gingivitis (mean GI: 0.2 - 1.0)\n\n          -  Patients with complete natural \"Ramfjord-teeth\" or their replacement teeth\n\n          -  Caucasian\n\n          -  Signed Informed Consent\n\n        Exclusion Criteria:\n\n          -  Patients with severe systemic diseases (diabetes, hepatitis, HIV, tuberculosis,\n             cancer)\n\n          -  Patients who require endocarditis prophylaxis for dental examination and treatment\n\n          -  Caries requiring treatment (e.g. caries with cavity) or other oral diseases (incl.\n             gingival hyperplasia, diseases of the oral mucosa, periodontal screening index PSI >\n             2)\n\n          -  Patients with orthodontic appliances and removable dentures\n\n          -  Patients treated with antibiotics less than 3 months prior to the baseline\n             examination at V1 and/or such a treatment planned for the duration of the trial\n\n          -  Patients chronically treated with steroids\n\n          -  Patients who suffer from xerostomia\n\n          -  Patients who regularly smoke more than 10 cigarettes per day\n\n          -  Patients who have a known hypersensitivity or allergy to the test product and its\n             ingredients or to medications that have a similar chemical structure\n\n          -  Participation of the patient in another clinical trial within the last four weeks\n             before enrollment in this trial\n\n          -  Incapability of assessing essence and possible consequences of the trial (e.g.\n             alcoholism)\n\n          -  Pregnant or breastfeeding women\n\n          -  Women with childbearing potential except those who fulfill the following criteria:\n\n               -  Post-menopausal (12 month of natural amenorrhoea or 6 months of amenorrhoea with\n                  Serum FSH > 40 U/ml)\n\n               -  Postoperative (6 weeks after bilateral ovariectomy with or without hysterectomy)\n\n               -  Continuous and correct application of a contraception method with a Pearl Index\n                  < 1% (e.g. implants, depots, oral contraceptives, intrauterine device - IUD)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02138552", 
            "org_study_id": "2013-002708-14"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "OCT 0.1% vs. Placebo", 
                    "OCT 0.15% vs. Placebo", 
                    "OCT 2.0% vs. Placebo"
                ], 
                "description": "Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo", 
                "intervention_name": "Octenidine dihydrochloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "OCT 0.1% vs. Placebo", 
                    "OCT 0.15% vs. Placebo", 
                    "OCT 2.0% vs. Placebo"
                ], 
                "description": "Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Octenidine"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Dresden", 
                        "country": "Germany", 
                        "zip": "01307"
                    }, 
                    "name": "Poliklinik f\u00fcr Parodontologie Med. Fakult\u00e4t C. G. Carus der TU Dresden"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "W\u00fcrzburg", 
                        "country": "Germany", 
                        "zip": "97070"
                    }, 
                    "name": "Abteilung f\u00fcr Parodontologie in der Poliklinik f\u00fcr Zahnerhaltung und Parodontologie der Universit\u00e4t W\u00fcrzburg"
                }
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "3", 
        "official_title": "Phase II Study to Assess Bacterial Count Reduction of Three Octenidine Mouthwash Concentrations in Comparison to a Placebo in Patients With Mild Gingivitis", 
        "overall_official": {
            "affiliation": "Poliklinik f\u00fcr Parodontologie Med. Fakult\u00e4t C. G. Carus der TU Dresden", 
            "last_name": "Katrin Lorenz, Dr.", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Bacterial count reduction is measured at V1 (Verum/Placebo) and V3 (Placebo/Verum) in a blinded cross-over design", 
            "measure": "Bacterial count reduction in saliva after a single application of OML in comparison to placebo application", 
            "safety_issue": "No", 
            "time_frame": "After 1 minute of rinsing"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02138552"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PI is measured at V2 (Verum/Placebo) and V4 (Placebo/Verum) in a blinded cross-over design", 
                "measure": "Mean plaque index (PI)", 
                "safety_issue": "No", 
                "time_frame": "After 5 days of application"
            }, 
            {
                "description": "GI is measured at V1/V2 (Verum/Placebo) and V3/V4 (Placebo/Verum) in a blinded cross-over design", 
                "measure": "Change in mean gingival index (GI)", 
                "safety_issue": "No", 
                "time_frame": "After 5 days of application"
            }, 
            {
                "measure": "Evaluation of taste and flavour (questionnaire)", 
                "safety_issue": "No", 
                "time_frame": "After 5 days of application"
            }, 
            {
                "measure": "AEs and SAEs", 
                "safety_issue": "Yes", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "Sch\u00fclke & Mayr GmbH", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sch\u00fclke & Mayr GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}